Design of the b3-adrenergic agonist treatment in chronic pulmonary hypertension secondary to heart failure trial

Combined pre-and post-capillary hypertension (CpcPH) is a relatively common complication of heart failure (HF) associated with a poor prognosis. Currently, there is no specific therapy approved for this entity. Recently, treatment with beta-3 adrenergic receptor (b3AR) agonists was able to improve p...

ver descrição completa

Detalhes bibliográficos
Autores: Garcia-Lunar, Inés, Blanco, Isabel, Fernández-Friera, Leticia, Prat-Gonzàlez, Susana, Jordà, Paloma, Sánchez, Javier, Pereda, Daniel, Pujadas, Sandra, Rivas-Lasarte, Mercedes, Solé-Gonzalez, Eduardo, Vázquez, Jorge, Blázquez, Zorba, García-Picart, Juan, Caravaca, Pedro, Escalera, Noemí, García Pavía, Pablo, Delgado, Juan, Segovia Cubero, Javier, Fuster Carulla, Valentí, Roig, Eulalia, Barberá, Joan Albert, Ibáñez, Borja, García-Álvarez, Ana
Formato: artículo
Fecha de publicación:2020
País:España
Recursos:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:repositorio.uam.es:10486/693269
Acesso em linha:http://hdl.handle.net/10486/693269
https://dx.doi.org/10.1016/j.jacbts.2020.01.009
Access Level:acceso abierto
Palavra-chave:Adrenoreceptors
Imaging
Pulmonary hypertension
Treatment
Medicina
Descrição
Resumo:Combined pre-and post-capillary hypertension (CpcPH) is a relatively common complication of heart failure (HF) associated with a poor prognosis. Currently, there is no specific therapy approved for this entity. Recently, treatment with beta-3 adrenergic receptor (b3AR) agonists was able to improve pulmonary hemodynamics and right ventricular (RV) performance in a translational, large animal model of chronic PH. The authors present the design of a phase II randomized clinical trial that tests the benefits of mirabegron (a clinically available b3AR agonist) in patients with CpcPH due to HF. The effect of b3AR treatment will be evaluated on pulmonary hemodynamics, as well as clinical, biochemical, and advanced cardiac imaging parameters. (Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure [SPHERE-HF];

Registos relacionados